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Abstract
Objectives To identify changes since 1994 in the
prevalence of resistance to anti›HIV drugs in primary
HIV›1 infections in the United Kingdom.
Design Retrospective and prospective assessment of
viruses obtained from people recently infected with HIV.
Setting Multiple centres (patients enrolled in the UK
register of seroconverters) and a single large HIV
clinic (active case ascertainment).
Participants 69 patients infected with HIV between
June 1994 and August 2000.
Main outcome measures Prevalence of key mutations
associated with drug resistance in the reverse
transcriptase and protease genes of HIV›1, by year of
infection.
Results Between June 1994 and August 2000, 10
(14%) of 69 newly infected patients had one or more
key HIV›1 mutations associated with drug resistance.
The risk of being infected with drug resistant virus
increased over time (adjusted relative risk per year
1.74 (95% confidence interval 0.93 to 3.27), P = 0.06).
The estimated prevalence of drug resistance in those
infected in 2000 was 27% (12% to 48%).
Conclusions Transmission of drug resistant HIV›1 in
the United Kingdom seems to be increasing. New
approaches to encourage safer sexual behaviour in all
sectors of the population are urgently needed.
Introduction
The incidence of AIDS and the mortality due to HIV›1
infection have declined dramatically in the United King›
dom since the introduction of highly active antiretroviral
drugs in 1996. In contrast, the incidence of new
infections has not decreased,1 and there is evidence of
increasing high risk sexual behaviour among homo›
sexual men in London.2 Since resistance to antiretroviral
drugs is known to emerge in some treated patients, there
is a risk that these virus variants may be transmitted, so
compromising treatment in newly infected individuals.3
We decided to estimate the prevalence of transmitted
(primary) resistance to anti›HIV drugs in the United
Kingdom and to identify changes since highly active
antiretroviral agents became available.
Participants and methods
Patients included in this study were a subset of those
enrolled in the UK register of HIV seroconverters, for
whom a stored serum or plasma sample was available
within 18 months of a negative result in an HIV
antibody test or who were found to be infected after
having had a negative result in an HIV antibody test in
the preceding 18 months.4 Patients fulfilling these
criteria who were found through active case ascertain›
ment at a single large clinic were also included. Partici›
pants had received no antiretroviral drugs at the time
of resistance testing. Nucleotide sequencing of the
reverse transcriptase and protease genes of plasma
virus, analysis, and subtype designations were under›
taken as previously described.5 Drug resistance was
defined as the presence of one or more key mutations
in reverse transcriptase or protease recognised as
being associated with reduced susceptibility to drugs.6
The midpoint between the dates of negative and
positive antibody tests was used as the date of serocon›
version. We used LOGXACT to perform logistic
regression analyses on individual patients’ data. We
examined the association between the presence of a
key mutation and the year of seroconversion, allowing
for the time intervals between the dates of negative and
positive antibody tests and the dates of negative and
resistance tests.
Results
Of 69 patients infected between June 1994 and August
2000 (the first 20 have been reported previously5), 60
were infected with subtype B virus (the major subtype in
Europe and North America) and nine by non›B (three
subtype A, five subtype C, one subtype D). Fifty eight
were infected through sex between men, nine (six
women) through sex between men and women, and two
(women) through self inflicted injury or injection. Ten
(14%) had evidence of reverse transcriptase or protease
gene mutations associated with drug resistance (table).
In two of the 10 cases, resistance against two of the three
available classes of antiretroviral agents was identified.
All 10 patients were white and were infected with
subtype B virus (nine through sex between men, one
through self inflicted injection). As patients with a key
mutation were significantly older than those in whom no
key mutation was found (mean age 39.1 years v 31.9
years, P = 0.02), we also included age as a factor in the
logistic regression analyses. We found evidence of an
increase in the risk of being infected with drug resistant
virus over time (adjusted relative risk per year 1.74, 95%
confidence interval 0.93 to 3.27; P = 0.06).
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Discussion
We report preliminary evidence of an increase in the
transmission of drug resistant HIV›1 over time in the
United Kingdom, with an estimated prevalence of 27%
(95% confidence interval 12% to 48%) in people
infected in 2000. It is important to study patients soon
after infection to obtain the best estimates of primary
drug resistance, because HIV continues to evolve after
transmission and resistant virus may be less likely to be
detected within the dominant plasma virus population
at later time points.
At least two factors are likely to contribute to these
findings. Firstly, highly active antiretroviral therapy is
used more often, and the prevalence of drug resistance
in people infected with HIV may be increasing.
Secondly, as unprotected sex among those at highest
risk of HIV infection increases, the likelihood of being
infected by a person who has taken antiretroviral drugs
is increased.
Nine patients with transmitted drug resistant virus
in our study were infected through sex between men.
However, the small numbers of other risk groups rep›
resented in our study preclude any firm conclusions
being drawn about differences between risk groups in
the transmission of resistant virus. Clearly, adherence
to treatment in people receiving highly active
antiretroviral therapy must be improved in order to
minimise the emergence of drug resistance.8 In
addition, further work is needed to evaluate the impact
of primary drug resistance on the outcome of HIV
infection in such individuals. Finally, new approaches
to encourage safer sexual behaviour within all sectors
of the population are urgently needed.
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What is already known on this topic
The emergence of HIV drug resistance in patients receiving
antiretroviral therapy is common
Transmission of virus variants resistant to anti›HIV drugs has been
documented
What this paper adds
The prevalence of transmitted HIV drug resistance in the United
Kingdom is increasing, exceeding 20% in 2000
New approaches to encourage safer sexual behaviour are urgently
needed
Prevalence and characteristics of primary HIV drug resistance in the UK 1994›2000
Estimated
year of
seroconversion
Total tested
(No with drug
resistance
mutations)
Key mutations associated with
drug resistance for each
patient identified
Drugs for which mutations
compromise efficacy
1994 1 (0) — —
1995 5 (0) — —
1996 15 (0) — —
1997 3 (1) RT: M41L, T215L Zidovudine
1998 10 (1) RT: M41L, T215Y Zidovudine
1999 9 (1) RT: M41L Zidovudine
2000 26 (7) RT: K219Q Zidovudine
RT: T69N Didanosine, zalcitabine
RT: Y181C Nevirapine, efavirenz
RT: M41L, V108I, T215D* Zidovudine, efavirenz, nevirapine
RT: M41L, K103N, Y188L, T215Y Zidovudine, efavirenz, nevirapine
PR: L90M Saquinavir, nelfinavir
RT: T215D* Zidovudine
RT=reverse transcriptase; PR=protease; C=cysteine; D=aspartic acid; I=isoleucine; K=lysine; L=leucine;
M=methionine; N=asparagine; Q=glutamine; T=threonine; V=valine; Y=tyrosine.
*Although the T215D mutation does not itself confer resistance, it reflects evolution from a transmitted
zidovudine resistant virus and is prone to re›emergence of resistance following initiation of therapy.7 It has
therefore been included in the table.
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